Gilead EVP reports 10b5‑1 option exercises and stock sales

Rhea-AI Filing Summary

Gilead Sciences (GILD) disclosed insider activity by its EVP, Corporate Affairs & GC, on 11/12/2025 pursuant to a Rule 10b5‑1 trading plan adopted on August 13, 2025. The officer exercised non‑qualified stock options and sold the resulting shares the same day.

Exercises were for 17,181 shares at $75.12, 35,965 shares at $60.75, and 500 shares at $60.75, followed by sales of equal amounts. Sale prices included $124 and weighted‑average prices of $122.302 and $122.904, with transaction ranges of $121.87–$122.83 and $122.88–$122.92. After these trades, 43,676 common shares were beneficially owned directly.

Insider Trade Summary

Net Seller: 53,646 shares ($6,590,487)

Net Sell 9 txns

Insider Telman Deborah H

Role EVP, Corporate Affairs & GC

Sold 53,646 shs ($6.59M)

Type	Security	Shares	Price	Value
Exercise	Non-qualified Stock Option (Right to Buy)	17,181	$0.00	--
Exercise	Non-qualified Stock Option (Right to Buy)	35,965	$0.00	--
Exercise	Non-qualified Stock Option (Right to Buy)	500	$0.00	--
Exercise	Common Stock	17,181	$75.12	$1.29M
Sale	Common Stock	17,181	$124.00	$2.13M
Exercise	Common Stock	35,965	$60.75	$2.18M
Sale	Common Stock	35,965	$122.302	$4.40M
Exercise	Common Stock	500	$60.75	$30K
Sale	Common Stock	500	$122.904	$61K

Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 37,799 shares (Direct); Common Stock — 60,857 shares (Direct)

Footnotes (1)

1. The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Sales prices for the transactions reported here range from $121.87 to $122.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Sales prices for the transactions reported here range from $122.88 to $122.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Telman Deborah H

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Corporate Affairs & GC

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/12/2025		M(1)		17,181	A	$75.12	60,857	D
Common Stock	11/12/2025		S(1)		17,181	D	$124	43,676	D
Common Stock	11/12/2025		M(1)		35,965	A	$60.75	79,641	D
Common Stock	11/12/2025		S(1)		35,965	D	$122.302(2)	43,676	D
Common Stock	11/12/2025		M(1)		500	A	$60.75	44,176	D
Common Stock	11/12/2025		S(1)		500	D	$122.904(3)	43,676	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Option (Right to Buy)	$75.12	11/12/2025		M(1)			17,181	(4)	03/10/2034	Common Stock	17,181	$0	37,799	D
Non-qualified Stock Option (Right to Buy)	$60.75	11/12/2025		M(1)			35,965	(4)	07/25/2032	Common Stock	35,965	$0	12,655	D
Non-qualified Stock Option (Right to Buy)	$60.75	11/12/2025		M(1)			500	(4)	07/25/2032	Common Stock	500	$0	12,155	D

Explanation of Responses:

1. The transactions reported in the Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

2. Sales prices for the transactions reported here range from $121.87 to $122.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

3. Sales prices for the transactions reported here range from $122.88 to $122.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

4. The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Deborah H. Telman	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Gilead (GILD) report?

An officer exercised non‑qualified stock options and sold the resulting shares on 11/12/2025 under a Rule 10b5‑1 trading plan.

Which officer at Gilead (GILD) was involved?

The reporting person is the EVP, Corporate Affairs & GC.

What option exercises occurred for Gilead (GILD)?

Exercises were for 17,181 shares at $75.12, 35,965 shares at $60.75, and 500 shares at $60.75.

At what prices were Gilead (GILD) shares sold?

Sales included $124 and weighted‑average prices of $122.302 and $122.904. Reported ranges were $121.87–$122.83 and $122.88–$122.92.

How many Gilead (GILD) shares were owned after the transactions?

Following the reported trades, 43,676 common shares were beneficially owned directly.

Was a trading plan used for the Gilead (GILD) insider sales?

Yes. The transactions were made pursuant to a Rule 10b5‑1 plan adopted on August 13, 2025.